94 related articles for article (PubMed ID: 24010918)
1. Epidemiology and risk factors for infections in myelodysplastic syndromes.
Sullivan LR; Sekeres MA; Shrestha NK; Maciejewski JP; Tiu RV; Butler R; Mossad SB
Transpl Infect Dis; 2013 Dec; 15(6):652-7. PubMed ID: 24010918
[TBL] [Abstract][Full Text] [Related]
2. Infection in the myelodysplastic syndromes.
Pomeroy C; Oken MM; Rydell RE; Filice GA
Am J Med; 1991 Mar; 90(3):338-44. PubMed ID: 2003516
[TBL] [Abstract][Full Text] [Related]
3. Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database.
Wilson AB; Neogi T; Prout M; Jick S
Cancer Epidemiol; 2014 Oct; 38(5):544-9. PubMed ID: 25189344
[TBL] [Abstract][Full Text] [Related]
4. Defining incidence, risk factors, and impact on survival of central line-associated blood stream infections following hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Lukenbill J; Rybicki L; Sekeres MA; Zaman MO; Copelan A; Haddad H; Fraser T; DiGiorgio MJ; Hanna R; Duong H; Hill B; Kalaycio M; Sobecks R; Bolwell B; Copelan E
Biol Blood Marrow Transplant; 2013 May; 19(5):720-4. PubMed ID: 23380342
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.
Breccia M; Federico V; Latagliata R; Mercanti C; D'Elia GM; Cannella L; Loglisci G; Salaroli A; Santopietro M; Alimena G
Leuk Res; 2011 Feb; 35(2):159-62. PubMed ID: 20594593
[TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
7. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
Merkel D; Filanovsky K; Gafter-Gvili A; Vidal L; Aviv A; Gatt ME; Silbershatz I; Herishanu Y; Arad A; Tadmor T; Dally N; Nemets A; Rouvio O; Ronson A; Herzog-Tzarfati K; Akria L; Braester A; Hellmann I; Yeganeh S; Nagler A; Leiba R; Mittelman M; Ofran Y
Am J Hematol; 2013 Feb; 88(2):130-4. PubMed ID: 23345248
[TBL] [Abstract][Full Text] [Related]
8. Case-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese population.
Lv L; Lin G; Gao X; Wu C; Dai J; Yang Y; Zou H; Sun H; Gu M; Chen X; Fu H; Bao L
Am J Hematol; 2011 Feb; 86(2):163-9. PubMed ID: 21264898
[TBL] [Abstract][Full Text] [Related]
9. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
10. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
11. A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers.
De Roos AJ; Deeg HJ; Davis S
Cancer Causes Control; 2007 Dec; 18(10):1199-208. PubMed ID: 17823848
[TBL] [Abstract][Full Text] [Related]
12. Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors.
Kaplan HG; Malmgren JA; Li CI; Calip GS
Breast Cancer Res Treat; 2013 Dec; 142(3):629-36. PubMed ID: 24265034
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome.
Gonzalez-Porras JR; Cordoba I; Such E; Nomdedeu B; Vallespi T; Carbonell F; Luño E; Ardanaz M; Ramos F; Pedro C; Gomez V; de Paz R; Sanchez-Barba M; Sanz GF; Del Cañizo AC;
Cancer; 2011 Dec; 117(24):5529-37. PubMed ID: 21638279
[TBL] [Abstract][Full Text] [Related]
14. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune manifestations associated with myelodysplastic syndrome predict a poor prognosis.
Arinobu Y; Kashiwado Y; Miyawaki K; Ayano M; Kimoto Y; Mitoma H; Akahoshi M; Miyamoto T; Horiuchi T; Akashi K; Niiro H
Medicine (Baltimore); 2021 Apr; 100(13):e25406. PubMed ID: 33787649
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
17. Increased intracellular activity of matrix metalloproteinases in neutrophils may be associated with delayed healing of infection without neutropenia in myelodysplastic syndromes.
Yamaguchi N; Ito Y; Ohyashiki K
Ann Hematol; 2005 Jun; 84(6):383-8. PubMed ID: 15711801
[TBL] [Abstract][Full Text] [Related]
18. Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis.
Adrianzen-Herrera D; Sparks AD; Singh R; Alejos-Castillo D; Batra A; Glushakow-Smith S; Pradhan K; Shastri A; Zakai NA
Blood Adv; 2023 Nov; 7(22):6913-6922. PubMed ID: 37729616
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndrome incidence, transfusion dependence, health care use, and complications: an Australian population-based study 1998 to 2008.
McQuilten ZK; Polizzotto MN; Wood EM; Sundararajan V
Transfusion; 2013 Aug; 53(8):1714-21. PubMed ID: 23305556
[TBL] [Abstract][Full Text] [Related]
20. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
